Organon & Co. (NYSE:OGN) Reaches New 12-Month High – Time to Buy?

Organon & Co. (NYSE:OGN) shares reached a new 52-week high during trading on Friday . The company traded as high as $13.60 and last traded at $13.5950, with a volume of 2403529 shares changing hands. The stock had previously closed at $13.55.

Analyst Ratings Changes

OGN has been the topic of a number of recent analyst reports. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and upped their target price for the company from $5.00 to $14.00 in a report on Tuesday, April 28th. BNP Paribas Exane reaffirmed a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Weiss Ratings downgraded shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Organon & Co. has a consensus rating of “Reduce” and an average target price of $11.40.

Organon & Co. Stock Performance

The company has a 50-day simple moving average of $13.49 and a two-hundred day simple moving average of $10.58. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.42 and a current ratio of 1.95. The firm has a market capitalization of $3.57 billion, a P/E ratio of 17.66, a PEG ratio of 1.26 and a beta of 1.55.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.’s dividend payout ratio (DPR) is presently 10.39%.

Institutional Investors Weigh In On Organon & Co.

Several hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in Organon & Co. by 87.8% in the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares in the last quarter. Allied Private Wealth LLC bought a new stake in shares of Organon & Co. during the 2nd quarter valued at $33,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of Organon & Co. during the 4th quarter valued at $44,000. Kestra Advisory Services LLC bought a new stake in shares of Organon & Co. during the 4th quarter valued at $47,000. Finally, WNY Asset Management LLC purchased a new stake in shares of Organon & Co. in the 1st quarter worth about $64,000. 77.43% of the stock is currently owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.